Ankylosing Spondylitis Market Research Report present a detailed analysis of the market listing Ankylosing Spondylitis Epidemiology, Drug therapies,  pipeline and companies.

Ankylosing Spondylitis Market Outlook and Forecast to 2032

Ankylosing Spondylitis Market

1. Key Insights
2. Executive Summary of Ankylosing Spondylitis (AS)
3. Disease Background and Overview: Ankylosing Spondylitis (AS)
3.1. Introduction
3.2. Severity based classification
3.2.1. Mild or early ankylosing spondylitis:
3.2.2. Severe or advanced AS:
3.3. Biology and pathology of AS
3.4. Etiology
3.4.1. Endogenous Factors
3.4.2. Exogenous Factors
3.5. Risk Factors of AS
3.5.1. Gender
3.5.2. Family History
3.5.3. Genetic Predisposition
3.5.4. Age
3.6. Signs and symptoms of AS
3.7. Genetics of ankylosing spondylitis &mdash; insights into pathogenesis
3.7.1. HLAB27 causing AS:
3.7.2. Antigen processing and presentation:
3.7.3. IL-17 and type 3 immunity in AS:
3.7.4. IL-17:
3.7.4.1. &gamma;&delta; T cells:
3.7.4.2. KIR3DL2+ T cells:
3.7.4.3. NKT cells:
3.7.4.4. Mast cells and neutrophils:
3.7.4.5. CD4 and CD8 T-cells:
3.7.5. IL-23 signaling:
3.7.6. Targeting type-3 immunity in AS:
3.8. Biomarkers
3.8.1. Genetic biomarkers
3.8.2. Markers for inflammation
3.8.3. Cartilage Turnover Markers
3.8.4. Other Biomarkers
3.9. Diagnosis
3.9.1. Examination
3.9.2. Genetics
3.9.3. Laboratory Findings
3.9.4. Imaging
3.9.5. Osteoporosis and Fracture
3.9.6. Observation
3.9.7. Mobility Testing
3.9.8. Strength Testing
3.9.9. Spine examination
3.10. Diagnostic Criteria
3.10.1. New York Classification Criteria: Diagnostic Criteria
4. Case Reports
4.1. Spinal subdural hematoma and ankylosing spondylitis: Case report and review of literature
4.2. Oral rehabilitation of a patient with ankylosing spondylitis and orofacial pain: A case report
5. Patient Journey
6. Epidemiology and Patient Population
6.1. KOL Views
6.2. Epidemiology Methodology
6.3. United States
6.3.1. Assumptions and Rationale
6.3.2. Total Prevalence of Ankylosing Spondylitis in the United States
6.3.3. Diagnosed Prevalence of Ankylosing Spondylitis in the United States
6.3.4. Gender-specific Diagnosed Prevalence of Ankylosing spondylitis in the United States
6.3.5. Age-specific Diagnosed Prevalence of Ankylosing spondylitis in the United States
6.3.6. Gene-specific Diagnosed Prevalence of Ankylosing Spondylitis in the United States
7. Current Treatment and Medical Practices
7.1. Therapy
7.2. Surgery
7.3. Lifestyle and home remedies
7.4. General Principles of Management
7.5. Treatment algorithm
7.6. Treatment Guidelines
7.6.1. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of AS and Nonradiographic Axial Spondyloarthritis
8. Unmet needs
9. Marketed drugs
9.1. Key cross competition- Marketed drugs
9.2. Cimzia (Certolizumab pegol): UCB
9.2.1. Drug Description
9.2.2. Regulatory Milestones
9.2.3. Other Developmental Activities
9.2.4. Clinical Development
9.2.4.1. Clinical Trials Information
9.2.5. Safety and Efficacy
9.2.6. Product Profile
9.3. Humira (adalimumab): AbbVie
9.3.1. Drug Description
9.3.2. Regulatory Milestones
9.3.3. Other Developmental Activities
9.3.4. Clinical Development
9.3.4.1. Clinical Trials Information
9.3.5. Safety and Efficacy
9.3.6. Product Profile
9.4. Celebrex (celecoxib): Pfizer
9.4.1. Drug Description
9.4.2. Regulatory Milestones
9.4.3. Other Developmental Activities
9.4.4. Clinical Development
9.4.4.1. Clinical Trials Information
9.4.5. Safety and Efficacy
9.4.6. Product Profile
9.5. Enbrel (Etanercept): Amgen/Pfizer
9.5.1. Drug Description
9.5.2. Regulatory Milestones
9.5.3. Other Developmental Activities
9.5.4. Clinical Development
9.5.4.1. Clinical Trials Information
9.5.5. Safety and Efficacy
9.5.6. Product Profile
9.6. Remicade (Infliximab): Janssen Biotech
9.6.1. Drug Description
9.6.2. Regulatory Milestones
9.6.3. Other Developmental Activities
9.6.4. Clinical Development
9.6.4.1. Clinical Trials Information
9.6.5. Safety and Efficacy
9.6.6. Product Profile
9.7. Simponi (Golimumab): Janssen Biotech
9.7.1. Drug Description
9.7.2. Regulatory Milestones
9.7.3. Other Developmental Activities
9.7.4. Clinical Development
9.7.4.1. Clinical Trials Information
9.7.5. Safety and Efficacy
9.7.6. Product Profile
9.8. Vimovo (naproxen and esomeprazole magnesium): Pozen
9.8.1. Drug Description
9.8.2. Regulatory Milestones
9.8.3. Other Developmental Activities
9.8.4. Clinical Development
9.8.4.1. Clinical Trials Information
9.8.5. Safety and Efficacy
9.8.6. Product Profile
9.9. Cosentyx: Novartis
9.9.1. Drug Description
9.9.2. Regulatory Milestones
9.9.3. Other Developmental Activities
9.9.4. Clinical Development
9.9.4.1. Clinical Trials Information
9.9.5. Safety and Efficacy
9.9.6. Product Profile
9.10. Indocin: Iroko Pharmaceuticals
9.10.1. Drug Description
9.10.2. Safety and Efficacy
9.10.3. Product Profile
9.11. Naprelan: Syntex Pharmaceuticals
9.11.1. Drug Description
9.11.2. Other Developmental Activities
9.11.3. Product Profile
9.12. Rayos (Prednisone): Horizon Pharma
9.12.1. Drug Description
9.12.2. Regulatory Milestones
9.12.3. Other Developmental Activities
9.12.4. Product Profile
9.13. Taltz (ixekizumab): Eli Lilly and Company
9.13.1. Drug Description
9.13.2. Regulatory Milestones
9.13.3. Other Development Activities
9.13.4. Clinical Development
9.13.4.1. Clinical Trials Information
9.13.5. Safety and Efficacy
9.13.6. Product Profile
10. Emerging Therapies
10.1. Key cross competition- Emerging Therapies
10.2. Tofacitinib: Pfizer
10.2.1. Product Description
10.2.2. Other Developmental Activities
10.2.3. Clinical Development
10.2.3.1. Clinical Trials Information
10.2.4. Safety and Efficacy
10.2.5. Product Profile
10.3. Bimekizumab: UCB Biopharma
10.3.1. Product Description
10.3.2. Other Developmental Activities
10.3.3. Clinical Development
10.3.3.1. Clinical Trials Information
10.3.4. Safety and Efficacy
10.3.5. Product Profile
10.5. Ilumya (Tildrakizumab): Sun Pharma Global
10.5.1. Product Description
10.5.2. Other Developmental Activities
10.5.3. Clinical Development
10.5.3.1. Clinical Trials Information
10.5.4. Product Profile
10.6. Namilumab: Izana Bioscience
10.6.1. Product Description
10.6.2. Other Developmental Activities
10.6.3. Clinical Development
10.6.3.1. Clinical Trials Information
10.6.4. Product Profile
10.7. ILT-101(Interleukin 2): Iltoo Pharma
10.7.1. Product Description
10.7.2. Other Developmental Activities
10.7.3. Clinical Development
10.7.3.1. Clinical Trials Information
10.7.4. Safety and Efficacy
10.7.5. Product Profile
10.8. Brodalumab (KHK4827): Kyowa Kirin
10.8.1. Product Description
10.8.2. Other Developmental Activities
10.8.3. Clinical Development
10.8.3.1. Clinical Trials Information
10.8.4. Safety and Efficacy
10.8.5. Product Profile
10.9. Rinvoq (Upadacitinib): Abbvie
10.9.1. Product Description
10.9.2. Other Developmental Activities
10.9.3. Clinical Development
10.9.3.1. Clinical Trials Information
10.9.4. Safety and Efficacy
10.9.5. Product Profile
11. Failed Therapies
11.1. Filgotinib: Galapagos/Gilead
11.1.1. Product Description
11.1.2. Other Developmental Activities
11.1.3. Clinical Development
11.1.3.1. Clinical Trials Information
11.1.4. Safety and Efficacy
11.1.5. Product Profile
12. Potential of Emerging Therapies and Current therapies
13. Attribute Analysis
14. Key Market Forecast Assumptions
15. Market Methodology
16. Ankylosing Spondylitis (AS): United States Market Outlook
16.1. United States Market Size
16.1.1. The total market size of Ankylosing Spondylitis
16.1.2. Market Size of Ankylosing Spondylitis by therapies
16.1.2.1. Market Size of Ankylosing Spondylitis by Class
17. Market Drivers
18. Market Barriers
19. SWOT Analysis
20. Reimbursement and Market access
21. Appendix
21.1. Bibliography
21.2. Report Methodology
22. DelveInsight Capabilities
23. Disclaimer
24. About DelveInsight

DelveInsight’s ‘Ankylosing Spondylitis Market Insights, Epidemiology, and Market Forecast–2032’ report deliver an in-depth understanding of the AS, historical and forecasted epidemiology as well as the AS market trends in the United States.

Ankylosing Spondylitis Market Insight, Epidemiology and Market Forecast -2030

DelveInsight' s Ankylosing Spondylitis Market Insights, Epidemiology and Market Forecast - 2032 report provides the detailed overview of the disease and in depth understanding of historical..